Raymond James’ Reni Benjamin may scale back his expectations on INCY, but still bets on 24% in return potential for shares.
Incyte Corporation (NASDAQ:INCY) investors are heading for the hills, after the drug maker, along with its partner Eli Lilly (NYSE:LLY), announced that the FDA issued …
Incyte Corporation (NASDAQ:INCY) and Eli Lilly and Co (NYSE:LLY) announced that the U.S.
After Incyte Corporation (NASDAQ:INCY) announced positive clinical pipeline updates that had investors celebrating and shares soaring 9%, top analyst Eric Schmidt at Cowen …
Incyte Corporation (NASDAQ: INCY) and Merck (NYSE:MRK) announced the decision to advance the clinical development program investigating the combination of epacadostat, Incyte’s investigational oral …
Incyte Corporation (NASDAQ:INCY) and Merus NV (NASDAQ:MRUS) announced today that they have entered into a global, strategic collaboration agreement focused on the research, …
Incyte Corporation (NASDAQ:INCY) and Eli Lilly and Co (NYSE:LLY) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …
Incyte Corporation (NASDAQ:INCY) and Eli Lilly and Company (NYSE:LLY) announced new data analyses of two phase 3 trials, RA-BUILD and RA-BEAM, showing that …
Incyte Corporation (NASDAQ:INCY) reports 2016 third-quarter financial results, including strong revenue growth driven by increased sales of Jakafi® (ruxolitinib) in the U.S.
At the European Society for Medical Oncology (ESMO) conference, Incyte Corporation (NASDAQ:INCY) presented updated data from its Phase I trial of epacadostat and …
